DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zmvd7k/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Aciont Inc.
- ActiveSite Pharmaceuticals, Inc.
- Acucela Inc.
- Aerpio Therapeutics, Inc.
- Allergan Plc
- Ampio Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Avalanche Biotechnologies, Inc.
- Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
- Chong Kun Dang Pharmaceutical Corp.
- Dyax Corp.
- EyeGate Pharmaceuticals, Inc.
- EyeGene, Inc.
- F. Hoffmann-La Roche Ltd.
- Gene Signal International SA
- Genmab A/S
- Icon Bioscience, Inc.
- Kala Pharmaceuticals, Inc.
- Kowa Company, Ltd.
- Mabion SA
- MacuCLEAR, Inc.
- NicOx S.A.
- Oculis ehf
- Ohr Pharmaceutical Inc.
- Pfizer Inc.
- Quark Pharmaceuticals, Inc.
- R-Tech Ueno, Ltd.
- Regeneron Pharmaceuticals, Inc.
- Santen Pharmaceutical Co., Ltd.
- SciFluor Life Sciences, LLC
- Senju Pharmaceutical Co., Ltd.
- ThromboGenics NV
- Verseon Corporation
For more information visit http://www.researchandmarkets.com/research/zmvd7k/diabetic_macular
